Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;28(2):72–76. doi: 10.1002/clc.4960280206

Effect of preexisting statin use on expression of C‐reactive protein, adhesion molecules, interleukin‐6, and antioxidized low‐density lipoprotein antibody in patients with unstable angina undergoing coronary stenting

Young‐Cheoul Doo 1,✉, Sang‐Jin Han 1, Sung‐Woo Han 1, Woo‐Jung Park 1, Seung‐Hyuk Choi 1, Goo‐Yeong Cho 1, Kyung‐Soon Hong 1, Kyoo‐Rok Han 1, Nam‐Ho Lee 1, Dong‐Jin Oh 1, Kyu‐Hyung Ryu 1, Chong‐Yun Rim 1, Kwang‐Hahk Lee 1, Yung Lee 1
PMCID: PMC6654111  PMID: 15757077

Abstract

Background: Statins are believed to reduce coronary heart disease by mechanisms in addition to their well‐known cholesterol lowering effect.

Hypothesis: We studied the effect of statins on expression of C‐reactive protein (CRP), interleukin‐6 (IL‐6), adhesion molecules, and antioxidized low‐density lipoprotein antibody (anti‐oxLDL Ab) in patients with unstable angina (Braunwald class IIb or IIIb) undergoing coronary stenting.

Methods: Consecutive 50 patients with unstable angina were included in the study. We classified the study subjects as patients using statins (Group A, n = 20, men 10, mean age 62 years) and patients notusing statins (Group B, n= 30, men 15, mean age 60 years).

Results: Baseline levels of inflammatory markers were similar in the two groups. However, 24 h after coronary stenting, serum levels of CRP (2.00 vs. 4.63 mg/l, p < 0.05), intercellular adhesionmolecule‐1 (ICAM‐1) (217 vs. 261 ng/ml, p<0.01), and anti‐oxLDL Ab (8.97 vs. 12.96 U/ml, p < 0.05) were significantly higher in Group B than in Group A. Furthermore, 72 h after coronary stenting, serum levels of CRP (3.00 vs. 5.50 mg/l, p<0.01)and ICAM‐1 (222 vs. 277 ng/ml, p< 0.05) were significantly higher in Group B than in Group A.

Conclusions: Preexisting statin therapy plays a role in reducing the serum levels of CRP, IC AM‐1, and anti‐oxLDL Ab after coronary stenting in patients with unstable angina. These data support an anti‐inflammatory or plaque‐stabilizing effect of statin therapy.

Keywords: unstable angina, statin, inflammation, coronary stenting

Full Text

The Full Text of this article is available as a PDF (41.3 KB).

References

  • 1. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126 [DOI] [PubMed] [Google Scholar]
  • 2. Mehta JL, Saldeen TGP, Rand K: Interactive role of infection, inflammation, and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998; 31: 1217–1225 [DOI] [PubMed] [Google Scholar]
  • 3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979 [DOI] [PubMed] [Google Scholar]
  • 4. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E: C‐reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI11A substudy. J Am Coll Cardiol 1998; 31: 1460–1465 [DOI] [PubMed] [Google Scholar]
  • 5. Witztum JL, Steinberg D: Role of oxidized low‐density lipoprotein in atherogenesis. J Clin Invest 1991; 73: 155–167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Reaven PD: Mechanism of atherosclerosis: Role of LDL oxidation. Free Radic Diagn Med 1994; 366: 113–128 [DOI] [PubMed] [Google Scholar]
  • 7. Parumus DV, Brown DL, Mitchison MJ: Serum antibodies to oxidized low‐density lipoprotein and carotid in chronic periaortitis. Arch Pathol Lab Med 1990; 114: 383–387 [PubMed] [Google Scholar]
  • 8. Yla‐Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32–40 [DOI] [PubMed] [Google Scholar]
  • 9. Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E, Bellomo G: Specificity to autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993; 4: 1119–1122 [DOI] [PubMed] [Google Scholar]
  • 10. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, Yla‐Herttuala S, Luoma JS, Koivula T, Nikkare T: Autoantibodies against oxidized low‐density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23–27 [DOI] [PubMed] [Google Scholar]
  • 11. Cybulsky MI, Gimbrone MA: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788–790 [DOI] [PubMed] [Google Scholar]
  • 12. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P: An atherogenic diet rapidly induces VCAM‐1, a cytokine‐regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb Vasc Biol 1993; 13: 197–204 [DOI] [PubMed] [Google Scholar]
  • 13. Sakai A, Kume N, Nishi E, Tanoue K, Miyasaka M, Kita T: P‐selectin and vascular cell adhesion molecule‐1 are focally expressed in aortas of hyper‐cholesterolemic rabbits before intimal accumulation of macrophages and T‐lymphocytes. Arterioscler Thromb Vasc Biol 1997; 17: 310–316 [DOI] [PubMed] [Google Scholar]
  • 14. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A: The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis. J Pathol 1993; 171: 223–229 [DOI] [PubMed] [Google Scholar]
  • 15. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE: Vascular cell adhesion molecule‐1 is expressed in human coronary atherosclerotic plaques: Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993; 92: 945–951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Jang Y, Lincoff AM, Plow EF, Topol EJ: Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591–1601 [DOI] [PubMed] [Google Scholar]
  • 17. Ridker PM, Hennekens CH, Roitman‐Johnson B, Stamper MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule‐1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88–92 [DOI] [PubMed] [Google Scholar]
  • 18. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davies CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM‐1, ICAM‐1, and E‐selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 86: 4219–4225 [DOI] [PubMed] [Google Scholar]
  • 19. The Scandanavian Simvastatin Survival Study Group : Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
  • 20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
  • 21. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
  • 22. The Long‐Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of intial cholesterol levels. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
  • 23. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorf A, Stein EA, Kruyer W, Gotto AM: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
  • 24. Farmer JA, Gotto AM Jr: Dyslipidemia and the vulnerable plaque. Prog Cardiovasc Dis 2002; 44: 415–428 [DOI] [PubMed] [Google Scholar]
  • 25. Crisby M, Nordin‐Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications forplaque stabilization. Circulation 2001; 103: 926–933 [DOI] [PubMed] [Google Scholar]
  • 26. Sacks FM, Ridker PM: Lipid lowering and beyond: Results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Herz 1999; 24: 51–56 [DOI] [PubMed] [Google Scholar]
  • 27. Wheeler DC: Are there potential non‐lipid‐lowering uses of statins? Drugs 1998; 56: 517–522 [DOI] [PubMed] [Google Scholar]
  • 28. Kawsaki M, Takatsu H, Noda T, Sano K, Ito Y, Hayakawa K, Tsuchlya K, Arai M, Nishigaki K, Takemura G, Minatoguchi S, Fujiwara T, Fujiwara H: In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 2002; 105: 2487–2492 [DOI] [PubMed] [Google Scholar]
  • 29. Stefanadis C, Toutouzas K, Vavuranakis M, Tsiamis E, Tousoulis D, Panagiotakos DB, Vaina S, Pitsavos C, Toutouzas P: Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur Heart J 2002; 23: 1664–1669 [DOI] [PubMed] [Google Scholar]
  • 30. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES